Suggested Use:As a dietary supplement take 2 tablets twice daily on an empty
stomach or as directed by your health care professional.

Serrapeptase - 120 caps

Serrapeptase, also known as Serratio Peptidase, is a proteolytic enzyme that is
produced commercially in the laboratory and it is isolated from the microorganism,
Serratia E15. Originally it was found being used by silkworms to aid digestion and
dissolve its chrysalis. Serratia E15 can be used effectively for inflammation in all
forms. The uses are wide ranging and cover just about every condition that is affected
by inflammation and/or non-living tissue and is being used extensively in Asia and
Europe.

Serrrapeptase is a good alternative to salicylates (such as aspirin), ibuprofen, and
other NSAIDS as well as steroids- providing relief for those suffering with a wide array
of autoimmune diseases that affect the inflammatory response, including ulcerative
colitis, psoriasis, uveitis, allergies, and some forms of cancer.

Although steroidal and non-steroidal anti-inflammatory drugs may offer temporary,
symptomatic relief from pain, swelling and inflammation, they may also be immuno-
suppressive. They are known to have dangerous side effects. Serrapeptase, on the other
hand, eases pain and swelling with no inhibitory effects on prostaglandins and has no
gastrointestinal side effects.

Serrapeptase as an anti-inflammatory in Europe and Asia has been in clinical use for
over twenty five years. Treatment includes chronic sinusitis, elimination of broncho-
pulmonary secretions (the enzyme breaks down protein fibers, allowing mucous to thin),
sprains and torn ligaments, and other traumatic injuries, idiopathic edema, as well as
post-operative inflammation.

The late German physician, Dr. Hans Nieper, used Serrapeptase to treat arterial
blockage in his coronary patients, reporting that Serrapeptase also dissolves blood
clots, and causes varicose veins to shrink or diminish..

Some Studies

Studying postoperative swelling and pain reduction of the upper ankle joint, a test
was carried out in 3 randomized groups of 66 patients, each with fresh rupture of the
lateral ligament treated surgically between December 1986 and April 1987. The group
receiving Serrapeptase saw a 50% decrease in swelling on the third postoperative day.
Decreased pain, for the most part, correlated with reduction in swelling. The
Serrapeptase group became rapidly pain-free. The two control groups, using traditional
elevation of the leg, bed rest, with and without applications of ice, had no reduction
in swelling at that time. (Esch PM, Gerngross H, Fabian A, Fortachr Med,107(4):67.8, 71
-2 1989 Feb 10)